The latest price target for ADC Therapeutics (NYSE: ADCT) was reported by HC Wainwright & Co. on September 19, 2023. The analyst firm set a price target for $12.00 expecting ADCT to rise to within 12 months (a possible 1237.79% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for ADC Therapeutics (NYSE: ADCT) was provided by HC Wainwright & Co., and ADC Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADC Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADC Therapeutics was filed on September 19, 2023 so you should expect the next rating to be made available sometime around September 19, 2024.

While ratings are subjective and will change, the latest ADC Therapeutics (ADCT) rating was a reiterated with a price target of $0.00 to $12.00. The current price ADC Therapeutics (ADCT) is trading at is $0.90, which is within the analyst’s predicted range.

The latest price target for ADC Therapeutics (NYSE: ADCT) was reported by HC Wainwright & Co. on September 19, 2023. The analyst firm set a price target for $12.00 expecting ADCT to rise to within 12 months (a possible 1237.79% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for ADC Therapeutics (NYSE: ADCT) was provided by HC Wainwright & Co., and ADC Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADC Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADC Therapeutics was filed on September 19, 2023 so you should expect the next rating to be made available sometime around September 19, 2024.

While ratings are subjective and will change, the latest ADC Therapeutics (ADCT) rating was a reiterated with a price target of $0.00 to $12.00. The current price ADC Therapeutics (ADCT) is trading at is $0.90, which is within the analyst’s predicted range.

The latest price target for ADC Therapeutics (NYSE: ADCT) was reported by HC Wainwright & Co. on September 19, 2023. The analyst firm set a price target for $12.00 expecting ADCT to rise to within 12 months (a possible 1237.79% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for ADC Therapeutics (NYSE: ADCT) was provided by HC Wainwright & Co., and ADC Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADC Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADC Therapeutics was filed on September 19, 2023 so you should expect the next rating to be made available sometime around September 19, 2024.

While ratings are subjective and will change, the latest ADC Therapeutics (ADCT) rating was a reiterated with a price target of $0.00 to $12.00. The current price ADC Therapeutics (ADCT) is trading at is $0.90, which is within the analyst’s predicted range.

The latest price target for ADC Therapeutics (NYSE: ADCT) was reported by HC Wainwright & Co. on September 19, 2023. The analyst firm set a price target for $12.00 expecting ADCT to rise to within 12 months (a possible 1237.79% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for ADC Therapeutics (NYSE: ADCT) was provided by HC Wainwright & Co., and ADC Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADC Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADC Therapeutics was filed on September 19, 2023 so you should expect the next rating to be made available sometime around September 19, 2024.

While ratings are subjective and will change, the latest ADC Therapeutics (ADCT) rating was a reiterated with a price target of $0.00 to $12.00. The current price ADC Therapeutics (ADCT) is trading at is $0.90, which is within the analyst’s predicted range.

The latest price target for ADC Therapeutics (NYSE: ADCT) was reported by HC Wainwright & Co. on September 19, 2023. The analyst firm set a price target for $12.00 expecting ADCT to rise to within 12 months (a possible 1237.79% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for ADC Therapeutics (NYSE: ADCT) was provided by HC Wainwright & Co., and ADC Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADC Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADC Therapeutics was filed on September 19, 2023 so you should expect the next rating to be made available sometime around September 19, 2024.

While ratings are subjective and will change, the latest ADC Therapeutics (ADCT) rating was a reiterated with a price target of $0.00 to $12.00. The current price ADC Therapeutics (ADCT) is trading at is $0.90, which is within the analyst’s predicted range.

The latest price target for ADC Therapeutics (NYSE: ADCT) was reported by HC Wainwright & Co. on September 19, 2023. The analyst firm set a price target for $12.00 expecting ADCT to rise to within 12 months (a possible 1237.79% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for ADC Therapeutics (NYSE: ADCT) was provided by HC Wainwright & Co., and ADC Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADC Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADC Therapeutics was filed on September 19, 2023 so you should expect the next rating to be made available sometime around September 19, 2024.

While ratings are subjective and will change, the latest ADC Therapeutics (ADCT) rating was a reiterated with a price target of $0.00 to $12.00. The current price ADC Therapeutics (ADCT) is trading at is $0.90, which is within the analyst’s predicted range.

The latest price target for ADC Therapeutics (NYSE: ADCT) was reported by HC Wainwright & Co. on September 19, 2023. The analyst firm set a price target for $12.00 expecting ADCT to rise to within 12 months (a possible 1237.79% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for ADC Therapeutics (NYSE: ADCT) was provided by HC Wainwright & Co., and ADC Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADC Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADC Therapeutics was filed on September 19, 2023 so you should expect the next rating to be made available sometime around September 19, 2024.

While ratings are subjective and will change, the latest ADC Therapeutics (ADCT) rating was a reiterated with a price target of $0.00 to $12.00. The current price ADC Therapeutics (ADCT) is trading at is $0.90, which is within the analyst’s predicted range.

The latest price target for ADC Therapeutics (NYSE: ADCT) was reported by HC Wainwright & Co. on September 19, 2023. The analyst firm set a price target for $12.00 expecting ADCT to rise to within 12 months (a possible 1237.79% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for ADC Therapeutics (NYSE: ADCT) was provided by HC Wainwright & Co., and ADC Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADC Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADC Therapeutics was filed on September 19, 2023 so you should expect the next rating to be made available sometime around September 19, 2024.

While ratings are subjective and will change, the latest ADC Therapeutics (ADCT) rating was a reiterated with a price target of $0.00 to $12.00. The current price ADC Therapeutics (ADCT) is trading at is $0.90, which is within the analyst’s predicted range.